Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

doi:10.1097/COH.0b013e3283412515

Review

. 2011 Jan;6(1):80-5.

doi: 10.1097/COH.0b013e3283412515.

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Edward A Berger¹

Affiliations

Affiliation

¹ Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. edward_berger@nih.gov

PMID: 21242898
PMCID: PMC3388845
DOI: 10.1097/COH.0b013e3283412515

Review

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Edward A Berger. Curr Opin HIV AIDS. 2011 Jan.

. 2011 Jan;6(1):80-5.

doi: 10.1097/COH.0b013e3283412515.

Author

Edward A Berger¹

Affiliation

¹ Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. edward_berger@nih.gov

PMID: 21242898
PMCID: PMC3388845
DOI: 10.1097/COH.0b013e3283412515

Abstract

Purpose of review: HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described.

Recent findings: Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers.

Summary: These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a 'functional cure' whereby therapy can be stopped without viral rebound.

PubMed Disclaimer

Cited by

Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.
Dey B, Berger EA. Dey B, et al. Curr Opin HIV AIDS. 2015 May;10(3):207-13. doi: 10.1097/COH.0000000000000151. Curr Opin HIV AIDS. 2015. PMID: 25710815 Free PMC article. Review.
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
Zaidi A, Meng Q, Popkin D. Zaidi A, et al. Immunotherapy (Los Angel). 2015 Dec;1(1):104. doi: 10.4172/imt.1000104. Epub 2015 Nov 30. Immunotherapy (Los Angel). 2015. PMID: 27110598 Free PMC article.
Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.
Wang X, Xu H. Wang X, et al. Viruses. 2021 Feb 21;13(2):335. doi: 10.3390/v13020335. Viruses. 2021. PMID: 33670027 Free PMC article. Review.
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.
Donahue DA, Wainberg MA. Donahue DA, et al. Retrovirology. 2013 Feb 1;10:11. doi: 10.1186/1742-4690-10-11. Retrovirology. 2013. PMID: 23375003 Free PMC article. Review.
Targeted cytotoxic therapy kills persisting HIV infected cells during ART.
Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV. Denton PW, et al. PLoS Pathog. 2014 Jan;10(1):e1003872. doi: 10.1371/journal.ppat.1003872. Epub 2014 Jan 9. PLoS Pathog. 2014. PMID: 24415939 Free PMC article.

See all "Cited by" articles

References

1. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. Journal of Allergy and Clinical Immunology. 2008 Jul;122(1):22–28. - PMC - PubMed
1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–1307. - PubMed
1. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010 Jul;329(5988):174–180. - PubMed
1. Burton DR, Weiss RA. A boost for HIV vaccine design. Science. 2010 Aug;329(5993):770–773. - PubMed
1. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nature Biotechnology. 2007 Dec;25(12):1444–1454. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

ZIA AI000538-23/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. Journal of Allergy and Clinical Immunology. 2008 Jul;122(1):22–28. - PMC - PubMed

[2] Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. Journal of Allergy and Clinical Immunology. 2008 Jul;122(1):22–28. - PMC - PubMed

[3] Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–1307. - PubMed

[4] Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–1307. - PubMed

[5] Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010 Jul;329(5988):174–180. - PubMed

[6] Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010 Jul;329(5988):174–180. - PubMed

[7] Burton DR, Weiss RA. A boost for HIV vaccine design. Science. 2010 Aug;329(5993):770–773. - PubMed

[8] Burton DR, Weiss RA. A boost for HIV vaccine design. Science. 2010 Aug;329(5993):770–773. - PubMed

[9] Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nature Biotechnology. 2007 Dec;25(12):1444–1454. - PMC - PubMed

[10] Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nature Biotechnology. 2007 Dec;25(12):1444–1454. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Affiliation

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Author

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials